RYAH GROUP Inc. and OMNI Medical Services LLC announced they have signed a Master Distribution Agreement, whereby OMNI will supply RYAH's innovative solutions for use in US clinical trials and research studies of medical cannabis. Cannabis telehealth innovator, OMNI Medical Services LLC (OMNI), announced it has signed a non-exclusive master distribution agreement, enabling OMNI to market and sell the RYAH Group's innovative products in support of clinical research trials and studies throughout the United States. RYAH and OMNI would also like to update regarding an October 26, 2021 announcement of a non-binding letter of intent for RYAH to acquire 100% of the business and assets of Omni. Both parties agree that the potential acquisition is not of interest at this time, whereas the business synergies and collaboration potential continue to be of significant interest. RYAH would also like to update that it has received a second comment letter from the Ontario Securities Commission regarding the Failure-to-File Cease Trade Order (''FFCTO'') issued under National Policy 11-207. The OSC have requested further clarifications on documents submitted to date, which RYAH management is working to address, hoping to obtain the revocation of theFFCTO as soon as possible. RYAH will keep investors updated with regular news releases. In the time, the RYAH team is working diligently to develop the business and increase shareholder value, and developing the strategic relationship with OMNI is a key example of progress. For the past 10 years, physician-owned-and-operated OMNI has led the effort in helping patients manage their chronic pain using medical cannabis therapies. Now OMNI is poised to transition into advanced research trials for optimizing the use of medical cannabis using RYAH's unique portfolio of products. The agreement with RYAH enables OMNI to offer the world's only Internet of Things (IoT) ecosystem to control the cannabis dosing experience, capture, and monetize valuable data. RYAH's
unique technology includes the RYAH MDTM platform enabling doctors to remotely monitor and control their patients' dosing regimens using the RYAH Smart InhalerTM, an internationally certified medical device (MDSAP, ISO 13485). Users control vaping temperatures, and inhalation amounts, correlated based on marijuana strain date with specific THC and CBD doses, through the RYAH HealthTM mobile app, available from Apple and Google.